Compare MAMA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | PGEN |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 598.8M | 1.4B |
| IPO Year | 2011 | 2013 |
| Metric | MAMA | PGEN |
|---|---|---|
| Price | $15.02 | $3.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $19.00 | $8.33 |
| AVG Volume (30 Days) | 364.3K | ★ 4.2M |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | $95,420,129.00 | ★ $230,981,000.00 |
| Revenue This Year | $31.09 | $1,115.92 |
| Revenue Next Year | $16.12 | $81.04 |
| P/E Ratio | $117.46 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $7.75 | $1.38 |
| 52 Week High | $17.85 | $5.47 |
| Indicator | MAMA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 36.15 |
| Support Level | $14.43 | $3.49 |
| Resistance Level | $16.75 | $3.64 |
| Average True Range (ATR) | 0.65 | 0.27 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 69.52 | 7.39 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.